
https://www.science.org/content/blog-post/old-standbys
# Old Standbys (November 2005)

## 1. SUMMARY

The article reflects on the disappearance or reduced availability of familiar "safe drugs" that people grew up with, such as aspirin, acetaminophen, and penicillin. The author expresses concern that these established, well-understood medications seem to be less prevalent or accessible compared to newer pharmaceutical products. The piece appears to lament the shift away from these traditional, proven medications toward newer drugs, suggesting a sense of nostalgia for the medicines that had long track records of safety and effectiveness.

## 2. HISTORY

Following the 2005 article, the pharmaceutical landscape evolved in several important directions:

**Established Drugs' Fate:**
- Aspirin, acetaminophen, and penicillin remained widely available and continued to be among the most commonly used medications globally
- These drugs maintained their status as essential medicines in healthcare systems worldwide
- Studies continued to reveal new applications (e.g., aspirin's cardiovascular benefits beyond pain relief)

**Safety Concerns:**
- Acetaminophen faced increased scrutiny over hepatotoxicity risks at high doses, leading to FDA warnings and dosage restrictions in some formulations
- Penicillin allergy concerns persisted, though true allergy prevalence was found to be lower than previously thought
- COX-2 inhibitors and other newer pain medications faced their own significant safety controversies, with some being withdrawn from the market

**Market Dynamics:**
- Generic versions of these classic drugs became even more prevalent due to patent expirations
- The pharmaceutical industry continued focusing on novel drugs with patent protection rather than improved formulations of existing drugs

## 3. PREDICTIONS

While the article expresses concern, it doesn't make specific testable predictions about the future of these drugs. However, the implied concern was that these "old standby" medications might become less available or be replaced entirely by newer alternatives.

**What actually happened:**
• These medications did not disappear - they remained fundamental to medical practice
• Instead of replacement, they became even more entrenched as first-line treatments
• Newer drugs often failed to demonstrate superior safety profiles compared to these established medications
• Many blockbuster drugs introduced around 2005 faced serious safety issues and withdrawals, reinforcing the value of proven medications

The broader concern about pharmaceutical innovation focusing on patentable rather than optimal treatments proved partly accurate, as evidenced by continued debates about drug pricing and the balance between innovation and access to proven medications.

## 4. INTEREST

Rating: **3/10**

The article addresses important questions about drug availability and pharmaceutical priorities, but the specific framing around "disappearing" established drugs didn't align with what actually occurred, as these medications remained central to medical practice.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20051121-old-standbys.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_